Opponents said the law improperly delegated the state's authority to the schools and allowed the companies to avoid the rigorous selection process under which existing commercial cannabis growers and dispensaries had been subjected. The rewritten law also does not specify what constitutes research or call for disclosure about possible payments made from the companies to the medical schools. Critics said the lack of disclosure risked the possibility of pay-to-play.